Authors
Ibrahim Abubakar, Matteo Zignol, Dennis Falzon, Mario Raviglione, Lucica Ditiu, Susan Masham, Ifedayo Adetifa, Nathan Ford, Helen Cox, Stephen D Lawn, Ben J Marais, Timothy D McHugh, Peter Mwaba, Matthew Bates, Marc Lipman, Lynn Zijenah, Simon Logan, Ruth McNerney, Adam Zumla, Krishna Sarda, Payam Nahid, Michael Hoelscher, Michel Pletschette, Ziad A Memish, Peter Kim, Richard Hafner, Stewart Cole, Giovanni Battista Migliori, Markus Maeurer, Marco Schito, Alimuddin Zumla
Publication date
2013/6/1
Source
The Lancet infectious diseases
Volume
13
Issue
6
Pages
529-539
Publisher
Elsevier
Description
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable …
Scholar articles
I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu… - The Lancet infectious diseases, 2013